Lupin Analyst Rating
based on 36 analysts
52.78%
Buy
27.78%
Hold
19.44%
Sell
Based on 36 analysts offering long term price targets for Lupin. An average target of ₹2235.5
Source: S&P Global Market Intelligence
Lupin Share analysis
Lupin price forecast by 36 analysts
Upside of5.79%
High
₹2750
Target
₹2235.50
Low
₹1300
Lupin target price ₹2235.5, a slight upside of 5.79% compared to current price of ₹2113.15. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin revenue growth forecast
Expected growth rate Q1, FY2027:33.39%
Forecast
Actual
Including amortisation and stock based compensations
Lupin EPS growth forecast
EPS estimate Q1, FY2027:105.59%
Forecast
Actual
Source: S&P Global Market Intelligence
Lupin Performance
Day's Low
Day's High
₹2,068.05Day's Price Range₹2,12652 Week's Low
52 Week's High
₹1,368.2552-Week Price Range₹2,402.9
| Returns % | |
| 1 Month Return | + 0.67 % |
| 3 Month Return | -3.05 % |
| 1 Year Return | + 48.22 % |
| Market Stats | |
| Previous Close | ₹2,098.90 |
| Open | ₹2,098.90 |
| Volume | 2.89L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹95,759.07Cr |
Lupin Key Statistics
| P/E Ratio | 36.66 |
| PEG Ratio | 1.29 |
| Market Cap | ₹95,759.07 Cr |
| P/B Ratio | 3.58 |
| EPS | 42.47 |
| Dividend Yield | 0.49 |
| Sector | Pharmaceuticals |
| ROE | 11.92 |
Lupin Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹95,759.07 Cr | 37.68% | 0.51 | ₹1,935 Cr | ₹20,010 Cr | |
| BUY | ₹12,534.65 Cr | -3.67% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹67,752.08 Cr | 28.8% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹99,431.01 Cr | 54.52% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹58,008.46 Cr | 24.18% | 0.53 | NA | NA |
Lupin Mutual Fund Holdings
About Lupin
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Share Price: ₹2113.15 per share as on 17 Jan, 2025 04:01 PM
Market Capitalisation: ₹95,759.07Cr as of today
Revenue: ₹5,497.01Cr as on September 2024 (Q3 24)
Net Profit: ₹859.48Cr as on September 2024 (Q3 24)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Lupin Ltd
Lupin Ltd Stock Performance and Valuation Insights - 13 Jan, 2025
Lupin Ltd's stock has shown a 71% performance over the past year, with valuations at 36 times EPS (FY25). Expected EPS growth exceeds 40% until FY26, with ROEs projected to rise to 19% by FY27, supporting sustainable premium valuations.Lupin Gains FDA Approval for Generic Ivacaftor - 10 Jan, 2025
Lupin Ltd has received tentative approval from the US FDA for its generic version of Ivacaftor oral granules, used in cystic fibrosis treatment, which may lead to 180 days of exclusivity. Additionally, several pharmaceutical companies, including Lupin, are expected to achieve 20-45% earnings growth.Lupin Gains FDA Approvals and Compliance Report - 09 Jan, 2025
Lupin Ltd. shares rose after receiving an Establishment Inspection Report from the US FDA for its Pithampur facility. The company also gained tentative FDA approval for its generic Ivacaftor oral granules, which may lead to significant market opportunities.Lupin Secures FDA Approval for Pithampur Facility - 08 Jan, 2025
Lupin Ltd announced it received the Establishment Inspection Report from the US FDA for its Pithampur Unit-1, classified as Voluntary Action Indicated, reflecting compliance with quality standards.Lupin Ltd Hits All-Time High Amid Strong Growth - 02 Jan, 2025
On January 2, 2025, Lupin Ltd. reached an all-time high of Rs 2,372.85, reflecting a 69.90% annual increase. Analysts predict further upside, with strong market performance and consistent gains over eight days.Lupin Strengthens Diabetes Portfolio and Hits New High - 30 Dec, 2024
Lupin Ltd announced the acquisition of Huminsulin from Eli Lilly, enhancing its diabetes portfolio. The stock reached a new 52-week high, reflecting strong market performance.Lupin Stock Gains Momentum Amid Positive Outlook - 24 Dec, 2024
Lupin is experiencing a strong earnings turnaround, driven by niche products and market performance. Analysts suggest buying for a target of Rs 2290 in the coming months.Lupin Secures FDA Approval and Reports Strong Earnings - 19 Dec, 2024
Lupin Ltd received FDA approval for its generic HIV treatment, leading to a 1% share price increase. The company reported significant revenue and profit growth for Q2 FY24 and allotted shares under ESOP, enhancing its capital structure.Lupin Secures FDA Approval for Generic HIV Tablets - 18 Dec, 2024
Lupin Ltd announced FDA approval for its generic version of Descovy tablets, allowing it to market emtricitabine and tenofovir alafenamide. The company is among the first to gain this approval, securing 180 days of shared exclusivity in the US market.Lupin Expands Market Share and Digital Health Services - 17 Dec, 2024
Lupin Ltd is gaining market share in Mirabegron with a new product launch and has partnered with Medicover Hospitals to enhance cardiac post-operative care through its digital platform, Lyfe.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 16.23% to 16.89% in Sep 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, LUPIN stock has moved up by 4.4%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 359.43 Cr → 852.63 Cr (in ₹), with an average increase of 30.6% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 19.32% to 21.50% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 4.99K Cr → 5.71K Cr (in ₹), with an average increase of 6.4% per quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 46.98% to 46.96% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.92% to 6.44% in Sep 2024 quarter
Lupin Financials
Index Inclusions
Lupin Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.96% | ||
| Foreign Institutions | 21.5% | 11.30 | |
| Mutual Funds | 16.89% | 4.06 | |
| Retail Investors | 6.44% | ||
| Others | 8.21% |
Lupin Key Indicators
Lupin Valuation
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (36.66x)
January 17, 2025
Industry (54.95x)
January 17, 2025
Highest (517.33x)
December 2, 2022
Lupin Earnings and Dividends
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 74.12% since last year same period to ₹852.63Cr in the Q2 2024-2025. On a quarterly growth basis, Lupin Ltd has generated 6.4% jump in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8 - translating a dividend yield of 0.57%.
Read More about Dividends
Lupin Technicals Summary
Bearish
Neutral
Bullish
Lupin Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Lupin Ltd
Lupin Ltd share price today stands at ₹2113.15, Open. ₹2098.9 ; Previous Close. ₹2098.9 ; High. ₹2126 ; Low. ₹2068.05 ; 52 Week High. ₹2402.9 ; 52 Week Low: ₹1368.25.
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Lupin Ltd shares.
Lupin Ltd is listed on NSE
Lupin Ltd is listed on BSE
- Today’s highest price of Lupin Ltd is ₹2126.
- Today’s lowest price of Lupin Ltd is ₹2068.05.
PE Ratio of Lupin Ltd is 36.66
PE ratio = Lupin Ltd Market price per share / Lupin Ltd Earnings per share
Today’s traded volume of Lupin Ltd(LUPIN) is 2.89L.
Today’s market capitalisation of Lupin Ltd(LUPIN) is ₹95759.07Cr.
| Lupin Ltd(LUPIN | Price |
|---|---|
52 Week High | ₹2402.9 |
52 Week Low | ₹1368.25 |
Lupin Ltd(LUPIN) share price is ₹2113.15. It is down -12.06% from its 52 Week High price of ₹2402.9
Lupin Ltd(LUPIN) share price is ₹2113.15. It is up 54.44% from its 52 Week Low price of ₹1368.25
| Lupin Ltd(LUPIN | Returns |
|---|---|
1 Day Returns | 14.25% |
1 Month Returns | 0.67% |
3 Month Returns | -3.05% |
1 Year Returns | 48.22% |